Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

NCT02719613

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 0020 Tucson, Arizona, United States
  • Local Institution - 0017 Bakersfield, California, United States
  • Local Institution - 0022 Fountain Valley, California, United States
  • Local Institution - 0016 West Hollywood, California, United States
View all 41 locations
View Trial Details
Completed

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT03935282

Conditions
Behavior, Breast Diseases, Breast Neoplasm, +42 more
Locations
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa, United States
  • Saint Louis Cancer and Breast Institute-Ballwin Ballwin, Missouri, United States
  • Mercy Hospital Springfield Springfield, Missouri, United States
View Trial Details
Completed

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

NCT02203643

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • IRCCS--CROB --CROB di Rionero in di Rionero in Vulture Rionero in Vulture, Italy
View Trial Details
Completed

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

NCT03213665

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, +91 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 117 locations
View Trial Details
Completed

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

NCT04557150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Peter MacCallum Cancer Center Melbourne, Victoria, Australia
  • UZ Gent Ghent, Belgium
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital Odense C, Denmark
View all 20 locations
View Trial Details
Completed

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Alabama Oncology Birmingham, Alabama, United States
  • Pacific Cancer Care Monterey, California, United States
  • American Oncology Partners of Maryland, PA Bethesda, Maryland, United States
  • Columbia University Medical Center New York, United States
View Trial Details

Related conditions